+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Biomarkers for Traumatic Brain Injury

  • ID: 4894742
  • Book
  • June 2020
  • Region: Global
  • 482 Pages
  • Elsevier Science and Technology
1 of 3

Biomarkers for Traumatic Brain Injury provides a comprehensive overview on the selection and implementation of serum-based biomarkers for traumatic brain injury. The book presents an economic analysis for implementing TBI biomarkers into clinical practice. In addition, it discusses the analytical tools needed to implement TBI biomarkers, including specifications for testing instruments and interpretative software. Neurologists, emergency department physicians, intensivists, and clinical laboratorians will find this book a great resource from which to familiarize themselves with the issues and processes regarding TBI biomarkers.

Approximately 2 million people in the U.S. sustain a traumatic brain injury (TBI) each year with over 250,000 hospitalizations and 50,000 deaths. There has been a significant rise in interest in diagnosing mild concussions, particularly in the sports world. While imaging has been the gold standard, these procedures are costly and not always available. There is great potential in using serum-based biomarkers, hence the book seeks to enlighten readers on new possibilities.

  • Offers strategies for the selection and implementation of traumatic brain injury biomarkers
  • Discusses the importance of autoantibodies and post translational modifications for TBI
  • Covers the analytical tools needed to implement TBI biomarkers, including the specifications for testing instruments and interpretative software
Note: Product cover images may vary from those shown
2 of 3

Section I. Introduction 1. Introduction
scope of the problem 2. The Need for TBI markers 3. Regulatory considerations for biomarkers of traumatic brain injury

Section II. Pathophysiology of TBI 4. Peripheral markers of TBI and blood-brain barrier disruption 5. The role of autoimmunity after TBI 6. Traumatic brain injury: Glial fibrillary acidic protein post-translational modification

Section III. TBI Biomarkers in Medical Practice 7. Economics of traumatic brain injury (TBI) biomarkers 8. Electrophysiology monitoring 9. TBI therapeutics

Section IV. Classical TBI Biomarkers 10. S100 Biomarkers in patients with TBI 11. Pathophysiology and clinical implementation of traumatic brain injury biomarkers: Neuron specific enolase 12. GFAP/UCHL1 13. NFL/NFH 14. Tau

Section V. Novel TBI Biomarkers 15. Neurogranin 16. Myelin basic protein in traumatic brain injury

Section VI. Analytical Testing Consideration 17. Antibody selection, evaluation and validation for analysis of traumatic brain injury biomarkers 18. Sensitivity immunoassay testing platforms 19. Clinical mass spectrometry and its applications in TBI 20. Surface plasmon reasonance 21. Point-of-care testing

Section VII. Non-Blood TBI Biomarker Strategy 22. Clinical risk factors of traumatic brain injury 23. Saliva 24. Digital neurocognitive testing 25. EEG as a bio-marker of concussion 26. Neuropsychological testing 27. Outpatient risk stratification for TBI 28. Peptidomics and traumatic brain injury: Biomarker utilities for a theragnostic approach 29. Autoantibodies in central nervous system trauma: New frontiers for diagnosis and prognosis biomarkers

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Wu, Alan
Dr. Alan Wu is a Professor of Laboratory Medicine at the University of California at San Francisco. He is the Co-Director of the Core Laboratory at the Zuckerberg San Francisco General Hospital. His research is focused on biomarkers of cardiovascular disease, clinical toxicology, and pharmacogenomics. In this capacity, his clinical and research laboratory conducts testing for routine analytes in blood, urine and cerebral spinal fluid for electrolytes, metabolites, hormones, proteins, and biomarkers. His particular area of interest is in cardiac biomarkers for acute cardiac diseases. He received a B.S. in both Chemistry and Biology at Purdue University and a Ph.D. in Analytical Chemistry at the University of Illinois. He was a professor at the University of Texas and the University of Connecticut prior to his current position at UCSF.
Peacock, W. Frank
W. Frank Peacock IV, MD, FACEP, FACC is a Professor of Emergency Medicine and Vice Chair for Research in the department of Emergency Medicine at Baylor College of Medicine, in Houston, Texas. He has >500 publications, is a two-time winner of the Best Research Paper of the Year Award from the American College of Emergency Physicians, and the 2019 Ray Bahr Award for Excellence from the American College of Cardiology. Finally, he is the founder of Comprehensive Research Associates, LLC, and Emergencies in Medicine, LLC.
Note: Product cover images may vary from those shown
Adroll
adroll